News

Astellas UK was suspended from membership of the Association of the British Pharmaceutical Industry (ABPI) with effect from 24 June 2016.  This has been extended for a further 12 months.

The report covers details of complaints made in 2017 and considered by the PMCPA in relation to the ABPI Code of Practice for the Pharmaceutical Industry. How many were received, who made them, their outcomes and sanctions

Proposals to amend the ABPI Code of Practice 2016 and the PMCPA Constitution and Procedure were agreed by ABPI members on 4 December 2018.

The President of the ABPI and the Director of the PMCPA have recently highlighted the need to ensure that advisory board meetings mee​t the requirements of the Code.​ ​

Disclosure template for 2018 data submissions

Further consultation on proposed changes to the ABPI Code of Practice for the Pharmaceutical Industry.

Proposals for amendment of the ABPI Code of Practice for the Pharmaceutical Industry and the PMCPA Constitution and Procedure were agreed at the Half Yearly General Meeting of the ABPI on 11 November. 

We are seeking to appoint a new independent member, from an independent body involved with providing information on medicines, to the Code of Practice Appeal Board in 2016.

Proposals to amend the ABPI Code of Practice for the Pharmaceutical Industry and the PMCPA Constitution and Procedure were agreed at the Half Yearly General Meeting of the ABPI on 11 November.  Further changes were agreed at a special meeting of the ABPI on 1 December.​

The 2016 Code can be downloaded here